Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just ...

And to sweeten the deal, the company's shares look reasonably valued right now. Amgen's forward price-to-earnings is around 14, compared to the healthcare industry's average of 16.3.

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a closer look by investors of all stripes. Amgen delivered stellar first ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Thousand Oaks, California-headquartered Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at ...

Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what to look for. Amgen ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

Amgen (AMGN) recently declared a $2.38 dividend per share, continuing its practice of rewarding shareholders, which aligns ...

Wednesday’s stock price rise was Amgen’s largest since July 20, 2005, when it reported a 38% quarterly profit jump.